Skip to content

Antibacterial Effect of Zinc Oxide Nanoparticles on Acinetobacter Baumannii Isolated From Patients With Hospital Acquired Infections in Sohag University Hospitals, Egypt

Antibacterial Effect of Zinc Oxide Nanoparticles on Acinetobacter Baumannii Isolated From Patients With Hospital Acquired Infections in Sohag University Hospitals, Egypt

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06628076
Enrollment
150
Registered
2024-10-04
Start date
2024-10-10
Completion date
2025-12-30
Last updated
2026-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infections, Nosocomial, Infections, Respiratory Tract

Keywords

A. baumannii., Biofilm, ZnO NPs, hospital aquired infections

Brief summary

A. baumannii is known as the most frequently isolated organism in intensive care units (ICUs), causing a variety of nosocomial infections, including pneumonia, urinary tract infections (UTIs), bacteremia as well as skin and soft tissue infections. These infections are usually associated with high mortality rates ranging between 26% among hospitalized patients and 43% among ICU patients.

Detailed description

Acinetobacter baumannii (A. baumannii) is Gram- negative, aerobic, glucose non-fermentative, non-motile coccobacillus, ubiquitous in nature, and persistent in healthcare settings. It is regarded as a significant opportunistic human pathogen. This bacterium become a growing problem in hospitals as a predominant multidrug-resistant (MDR) bacterium. Horizontal acquisition of resistance genes is the main factor involved in the emergence of MDR . There are many mechanisms to confer resistance to different classes of antibiotics in A. baumannii, one of them is multidrug efflux pumps. These efflux pumps are important source of MDR, which export antibiotics from the cell, increasing their antibiotic resistance. AdeABC is one of the most important efflux systems, belonging to the RND family in Acinetobacter, which plays an important role in the resistance to a broad group of antibiotics; its genes are chromosomal and encode three genes, i.e., AdeB, AdeA, and AdeC, forming an operon in the vicinity. In addition, the expression of AdeABC is done by a two-component system, which includes a response regulator (AdeR) and a sensor kinase (AdeS) . The ability of Acinetobacter spp. to form biofilm that enables bacterial survival in hospital settings, especially in ICUs, is the most significant contributing factor to their virulence, and this trait is also responsible for their notable antibiotic resistance. Several biofilm-related genes influence antimicrobial susceptibility, suggesting an association between the biofilm-forming ability of Acinetobacter spp. and their antibiotic resistance patterns (MDR/XDR) Zinc oxide nanoparticles (ZnO NPs) are one of the most important nanoparticles of metal oxides; it is a unique and inorganic materials that can be used in several biological applications (anti-bacterial, anti-inflammatory). ZnO NPs exhibit distinctive properties other than other nanoparticles such as higher solubility, better biofilm penetration and effective drug delivery . ZnO NPs have been reported to have antimicrobial properties such as disrupting the cell membrane of pathogens, accumulating in the cell and producing toxic H2O2 (hydrogen peroxide)

Interventions

Samples will be cultured on MacConkey agar. Morphological identifications of growth isolates by Gram staining, colony features and conventional biochemical tests. All isolates will be identified to species level using automated bacterial identification systems.

DIAGNOSTIC_TESTAntibiotic

Strains confirmed as A. baumannii will be examined for their different antibiotic susceptibility by modified Kirby Bauer\'s disc diffusion method on Mueller Hinton Agar.

DIAGNOSTIC_TESTBiofilm assessment

The biofilm formation activity of A. baumannii isolates will be tested using the microtitre plate technique

DIAGNOSTIC_TESTnanoparticle zinc oxide

Detection of the effect of ZnO NPs on the biofilm producer MDR A. baumannii strains using the same method

\- Evaluation the effect of ZnO NPs on the expression of some efflux pump genes, and biofilm related genes in MDR A. baumannii isolates using Real time PCR technology.

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
No minimum to 90 Years
Healthy volunteers
No

Inclusion criteria

* All patients suffering from infections that can be caused by A. baumannii.

Exclusion criteria

* All patients suffering from infections that aren\'t caused by A. baumannii.

Design outcomes

Primary

MeasureTime frameDescription
A. baumannii antibiotic susceptibility profileOctober 2024 to December 2025A. baumannii antibiotic susceptibility profile will be done using modified kirbybeur method
Isolation and identification of A. baumannii from different clinical samplesOctober 2024 to December 2025Isolation and identification of A. baumannii from different clinical samples using MacConKey medium, oxidase test. TSI, And automated identification ViteK system
A. baumannii strains which produce biofilmOctober 2024 to December 2025Detection of A. baumannii strains which produce biofilm using tissue culture plates and Gram stain
Ability of ZnO NPs to inhibit the phenomenon of biofilm formation by MDR A. baumannii strainsOctober 2024 to December 2025Assessment of ability of ZnO NPs to inhibit the phenomenon of biofilm formation by MDR A. baumannii strains using ZnO NPs to be applied by different concentrations on tissue culture plates and measure the degree of Biofilm formation using ELISA
The effect of ZnO NPs on the expression of some efflux pump genes and biofilm related genes in MDR A. baumannii strainsOctober 2024 to December 2025Evaluation the effect of ZnO NPs on the expression of some efflux pump genes and biofilm related genes in MDR A. baumannii strains using real time PCR(Polymerase Chain reaction)

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 14, 2026